Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 6, 2013, Pages 719-725

  Hsiao, Shih Hsin ^a   Chung, Chi Li ^a,b   Lee, Chi Ming ^a   Chen, Wei Yu ^c   Chou, Yu Ting ^d   Wu, Zhung Han ^a   Chen, Yi Chie ^a   Lin, Sey En ^a  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Epidermal growth factor receptor mutations; Genotyping; Non small cell lung cancer; Subtyping

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EXON; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG LESION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PNEUMOTHORAX; PREDICTIVE VALUE; SQUAMOUS CELL CARCINOMA; THORAX DRAINAGE;

EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS; GENOTYPING; NON-SMALL CELL LUNG CANCER; SUBTYPING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEASIBILITY STUDIES; FEMALE; GENES, ERBB-1; GENOTYPE; HUMANS; IMAGE-GUIDED BIOPSY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84887246299     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.06.002     Document Type: Article

References (40)

1. E. Gabrielson Worldwide trends in lung cancer pathology Respirology 11 2006 533 538
2. W.A. Cooper, S. O'Toole, and M. Boyer What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements Pathology 43 2011 103 115
3. K.M. Kerr Personalized medicine for lung cancer: new challenges for pathology Histopathology 60 2012 531 546
4. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
5. G. Scagliotti, N. Hanna, and F. Fossella The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 2009 253 263
6. D.H. Johnson, L. Fehrenbacher, and W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
7. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
8. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
9. M. Fukuoka, Y.L. Wu, and S. Thongprasert Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
10. C. Zhou, Y.L. Wu, and G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
11. A.T. Shaw, B.Y. Yeap, and B.J. Solomon Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 2011 1004 1012
12. R. Rosell, E. Carcereny, and R. Gervais Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
13. H. Shigematsu, L. Lin, and T. Takahashi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
14. M. Tokumo, S. Toyooka, and K. Kiura The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers Clin Cancer Res 11 2005 1167 1173
15. R. Rosell, T. Moran, and C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
16. Y. Miyamae, K. Shimizu, and J. Hirato Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma Oncol Rep 25 2011 921 928
17. B. Solomon, M. Varella-Garcia, and D.R. Camidge ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer J Thorac Oncol 4 2009 1450 1454
18. A.T. Shaw, B.Y. Yeap, and M. Mino-Kenudson Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
19. M.B. Beasley, and D.T. Milton ASCO Provisional Clinical Opinion: epidermal growth factor receptor mutation testing in practice J Oncol Pract 7 2011 202 204
20. R. Pirker, F.J. Herth, and K.M. Kerr Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop J Thorac Oncol 5 2010 1706 1713
21. M. Salto-Tellez, M.S. Tsao, and J.Y. Shih Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach J Thorac Oncol 6 2011 1663 1669
22. E. Thunnissen, K.M. Kerr, and F.J. Herth The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group Lung Cancer 76 2012 1 18
23. A.G. Nicholson, D. Gonzalez, and P. Shah Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis J Thorac Oncol 5 2010 436 441
24. S.H. Ou, and J.A. Zell Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies J Thorac Oncol 4 2009 1202 1211
25. G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
26. F. Laurent, V. Latrabe, and B. Vergier CT-guided transthoracic needle biopsy of pulmonary nodules smaller than 20 mm: results with an automated 20-gauge coaxial cutting needle Clin Radiol 55 2000 281 287
27. M.D. Guimaraes, M.Q. de Andrade, and A.C. da Fonte CT-guided cutting needle biopsy of lung lesions-an effective procedure for adequate material and specific diagnose Eur J Radiol 80 2011 e488 e490
28. M.D. Guimaraes, M.Q. Andrade, and A.C. Fonte Predictive complication factors for CT-guided fine needle aspiration biopsy of pulmonary lesions Clinics (Sao Paulo) 65 2010 847 850
29. W. Pao, and M. Ladanyi Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method Clin Cancer Res 13 2007 4954 4955
30. S.L. Edwards, C. Roberts, and M.E. McKean Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category J Clin Pathol 53 2000 537 540
31. R. Nizzoli, M. Tiseo, and F. Gelsomino Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer J Thorac Oncol 6 2011 489 493
32. N. Navani, J.M. Brown, and M. Nankivell Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients Am J Respir Crit Care Med 185 2012 1316 1322
33. N. Rekhtman, S.M. Brandt, and C.S. Sigel Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing J Thorac Oncol 6 2011 451 458
34. S.B. Solomon, M.F. Zakowski, and W. Pao Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis AJR Am J Roentgenol 194 2010 266 269
35. M.E. Arcila, G.R. Oxnard, and K. Nafa Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay Clin Cancer Res 17 2011 1169 1180
36. C.M. Chen, J.W. Chang, and Y.C. Cheung Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer Acta Radiol 49 2008 991 994
37. Y.C. Cheung, J.W. Chang, and J.J. Hsieh Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle Lung Cancer 67 2010 166 169
38. W.D. Travis, E. Brambilla, and M. Noguchi International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
39. A. Yoshizawa, N. Motoi, and G.J. Riely Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases Mod Pathol 24 2011 653 664
40. A. Warth, T. Muley, and M. Meister The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival J Clin Oncol 30 2012 1438 1446